ReviewDocumenta ophthalmologica. Advances in ophthalmology2012
The pathogenesis of early retinal changes of diabetic retinopathy.
Review in Documenta ophthalmologica. Advances in ophthalmology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03085771 (Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes), which is not on this map. Cited by 43 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Meta-Analysis of Relationship of Sleep Quality and Duration With Risk of Diabetic Retinopathy.Frontiers in endocrinology · 2022Pooled it
- Sleep apnea and eye diseases: evidence of association and potential pathogenic mechanisms.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2022Pooled it
- Two polymorphisms (rs699947, rs2010963) in the VEGFA gene and diabetic retinopathy: an updated meta-analysis.BMC ophthalmology · 2013Pooled it
- Trial
- The oscillatory response of the electroretinogram and neuronal adaptation.Acta ophthalmologica · 2026Review
- Effects of Selected Antioxidants on Electroretinography in Rodent Diabetic Retinopathy.Antioxidants (Basel, Switzerland) · 2024Review
- Changes in Waveguiding Cone Photoreceptors and Color Vision in Patients With Diabetes Mellitus.Investigative ophthalmology & visual science · 2024Article
- Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management.Advanced healthcare materials · 2024Review
- Resilience to diabetic retinopathy.Progress in retinal and eye research · 2024Review
- Electrophysiological findings in long-term type 1 diabetes patients without diabetic retinopathy using different ERG recording systems.Scientific reports · 2024Article
- Outer Retinal and Choroidal Changes in Adolescents with Long-Lasting Type 1 Diabetes.Journal of clinical medicine · 2023Article
- Retinal Functional Impairment in Diabetic Retinopathy.Biomedicines · 2023Article
- Oxidative Stress and Its Regulation in Diabetic Retinopathy.Antioxidants (Basel, Switzerland) · 2023Review
- Characterization of NLRP3 Inflammasome Activation in the Onset of Diabetic Retinopathy.International journal of molecular sciences · 2022Article
- Examining the Relationship Between Diabetic Macular Edema, and Obstructive Sleep Apnea.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Photoreceptor cells and RPE contribute to the development of diabetic retinopathy.Progress in retinal and eye research · 2021Review
- Neuroretinal dysfunction revealed by a flicker electroretinogram correlated with peripheral nerve dysfunction and parameters of atherosclerosis in patients with diabetes.Journal of diabetes investigation · 2021Article
- Noninvasive temporal detection of early retinal vascular changes during diabetes.Scientific reports · 2020Article
- Retinal Physiology and Circulation: Effect of Diabetes.Comprehensive Physiology · 2020Review
- Triamcinolone acetonide combined with aminoguanidine inhibits inflammation and oxidative stress, improves vascular endothelial and retinal function and reduces VEGF expression in diabetic retinopathy patients.Experimental and therapeutic medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent successful trials of antibodies to vascular endothelial growth factor (VEGF) in diabetic retinopathy implicate this cytokine as a major cause of diabetic retinopathy (DR) and diabetic macular oedema (DME). The mechanisms which cause VEGF to be over-expressed to cause the vasculopathy are not entirely clear. This review explores the earliest changes to the retina in DR and the factors that predispose or prevent DR, including sleep apnoea, receptor degenerations laser treatment and VEGF polymorphism. The review also presents the evidence that retinal hypoxia, existing in the earliest stages, causes DR. This hypoxia is much increased by dark adaptation, indicating a new and possibly superior therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.